Upstream Bio Q2 2026: $261M Cash, Phase 3 Trials on Track for Q1 2027, COPD Enrollment Complete

summarizeSummary

Upstream Bio reported Q2 2026 financials with $261.3 million in cash and provided clinical updates: Phase 3 trials in severe asthma and CRSwNP are on track for Q1 2027, COPD Phase 2 enrollment is complete, and additional positive CRSwNP data were presented. The company remains funded through 2027.

check_boxKey Events · Earnings and Guidance · UPB

• Q2 2026 Financial Results

  A net loss of $39.7 million was recorded on R&D spend of $36.1 million; cash, equivalents, and short-term investments stood at $261.3 million as of June 30, 2026, expected to fund operations through 2027.

• Phase 3 Trials on Track

  Initiation of Phase 3 trials in severe asthma and CRSwNP is planned for Q1 2027; End-of-Phase 2 interactions with the FDA are on schedule.

• COPD Phase 2 Enrollment Complete

  The VENTURE trial enrolled 481 participants; data are expected in the second half of 2027.

• Positive CRSwNP Data Presented

  At the ATS and EAACI congresses, verekitug showed clinically meaningful improvements in nasal polyp score (NPS) in ~80% of participants, with a 72% improvement in nasal congestion and an 83% improvement in total symptom score.

auto_awesomeAnalysis · UPB · Life Sciences

The Q2 update from Upstream Bio reveals a net loss of $39.7 million, consistent with expectations, and a robust cash position of $261.3 million that funds operations through 2027. Its lead candidate, verekitug, is advancing toward Phase 3 trials in severe asthma and CRSwNP in Q1 2027, with FDA interactions proceeding on schedule. Enrollment in the Phase 2 COPD trial is now complete, and additional positive data from the CRSwNP program were presented at recent medical congresses. These milestones de-risk the pipeline and keep the company on track for key data readouts in 2027, though the cash runway remains tight relative to the planned Phase 3 spend.